Внутрихромосомная амплификация 21q (iAMP21) как маркер неблагоприятного прогноза при острых лимфобластных лейкозах из В-линейных предшественников

Childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with intrachromosomal amplification of chromosome 21 (iAMP21) has very unfavorable prognosis when treated according as standard risk group, mainly due to high risk of relapce. The outcome is improoving dramatically when the patients were treated as high risk. In our study we analyzed clinical parameters and outcome in children with BCP-ALL and iAMP21 according to trial Moscow-Berlin 2008 (ALL-MB 2008). The majority of patients were stratified in standard and intermediate risk group. Seven years event free survival (EFS) in patients with iAMP21 and without iAMP21 was 0.48 ± 0.24 and 0,87 ± 0,2 respectively with cumulative incidence of relapse 0.41 ± 0.24 и 0.07 ± 0.2. BCP-ALL with iAMP21 needs some changes in current stratification strategy and new approaches to treatment. For faster and accurate detection of iAMP21 evaluation by FISH technique must be applied.